Abstracts tagged "Psoriatic arthritis"

Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Tobee Gunter¹ and Jessica Walsh², ¹Rheumatology, School of Medicine, University of Utah Internal Medicine, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…
Abstract Number: 2873 • 2015 ACR/ARHP Annual Meeting
Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Sofia Ramiro¹, Josef S. Smolen², Robert B.M. Landewé³, Désirée van der Heijde¹, Maxime Dougados⁴, Paul Emery⁵, Maarten de Wit⁶, Maurizio Cutolo⁷, Susan Oliver⁸ and Laure Gossec⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁶EULAR Social Leagues, Zurich, Switzerland, ⁷Division of Clinical Immunology, Dept Internal Medicine, University of Genova, Genova, Italy, ⁸Independent Nurse Consultant, North Devon, United Kingdom, ⁹Rheumatology, Pitié Salpetriere Hospital, Paris, France
Background/Purpose: As part of the update of the EULAR recommendations for the management of PsA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 675 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Ana Urruticoechea¹, Maria Auxiliadora Martin², Santos Castañeda³, Carlos Alberto Sánchez-Piedra², Carlos González-Juanatey⁴, Javier Llorca⁵, Federico Díaz-González⁶ and Miguel Angel Gonzalez-Gay⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: To study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD). Methods: Cross section…
Abstract Number: 2888 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Maurizio Cutolo⁶, Georg A. Schett⁷, Eric Lespessailles⁸, Melissa McIlraith⁹, ChiaChi Hu⁹, Christopher J. Edwards¹⁰, Charles A. Birbara¹¹ and Philip J. Mease¹², ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego School of Medicine, LaJolla, CA, ³University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶University of Genova, Genova, Italy, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Orléans, Orléans, France, ⁹Celgene Corporation, Warren, NJ, ¹⁰University Hospital Southampton, Southampton, United Kingdom, ¹¹University of Massachusetts Medical School, Worcester, MA, ¹²Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1, 2, and 3 compared apremilast (APR) efficacy/safety with placebo…
Abstract Number: 1595 • 2014 ACR/ARHP Annual Meeting
Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States
Thomas Tencer¹, Zoe Clancy¹, Helene Cawston², Sandrine Cure³ and Frank Zhang¹, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²OptumInsight, Nanterre, France, ³OptumInsight, Uxbridge, United Kingdom
Background/Purpose: In the treatment of psoriatic arthritis (PsA), switching between alternative biologic treatments is common. A cost-effectiveness model was developed to assess the impact of…
Abstract Number: 602 • 2014 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function
Alvin Wells¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Christopher J. Edwards⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
Abstract Number: 1590 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, ChiaChi Hu⁹, Randall M. Stevens⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California San Diego, La Jolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor that may modify the immune response, has been shown effective in psoriatic arthritis (PsA). PALACE 1 compared…
Abstract Number: 550 • 2014 ACR/ARHP Annual Meeting
Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Vibeke Strand¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, P. Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Psoriatic arthritis (PsA) has a significant adverse effect on patients’ health-related quality of life (HRQoL), affecting their physical and emotional functioning and psychological health.…
Abstract Number: 1586 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Kun Liang², Dafna D. Gladman³, Eleftherios Diamandis⁴ and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, Unviersity of Toronto, Mount Sinai Hospital, Ontario, Canada, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 548 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Maurizio Cutolo², Philip J. Mease³, Dafna D. Gladman⁴, Adewale O. Adebajo⁵, Juan Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Georg A. Schett⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher Edwards¹¹ and Charles A. Birbara¹², ¹University of California San Diego, La Jolla, CA, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁷Teaching Hospital of the University of Hamburg, University of Hamburg, Hamburg, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 1572 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Christopher J. Edwards¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Alvin Wells⁷, ¹University Hospital Southampton, Southampton, United Kingdom, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷Rheumatology & Immunotherapy Center, Franklin, WI
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Alice B. Gottlieb¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, Peter Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Tufts Medical Center, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].